C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 22 PLN Market Closed
Market Cap: 1.2B PLN

Wall Street
Price Targets

CLN Price Targets Summary
Celon Pharma SA

Wall Street analysts forecast CLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLN is 27.74 PLN with a low forecast of 15.66 PLN and a high forecast of 40.95 PLN.

Lowest
Price Target
15.66 PLN
29% Downside
Average
Price Target
27.74 PLN
26% Upside
Highest
Price Target
40.95 PLN
86% Upside
Celon Pharma SA Competitors:
Price Targets
NEULANDLAB
Neuland Laboratories Ltd
56% Upside
688166
BrightGene Bio-Medical Technology Co Ltd
13% Downside
600216
Zhejiang Medicine Co Ltd
15% Upside
300558
Betta Pharmaceuticals Co Ltd
0% Downside
1558
YiChang HEC ChangJiang Pharmaceutical Co Ltd
8% Downside
SDZ
Sandoz Group AG
6% Upside
GLENMARK
Glenmark Pharmaceuticals Ltd
18% Upside

Revenue
Forecast

Revenue Estimate
Celon Pharma SA

For the last 8 years the compound annual growth rate for Celon Pharma SA's revenue is 6%. The projected CAGR for the next 3 years is 17%.

6%
Past Growth
17%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Celon Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
23%
Average Beat

Net Income
Forecast

Net Income Estimate
Celon Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
9%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CLN's stock price target?
Price Target
27.74 PLN

According to Wall Street analysts, the average 1-year price target for CLN is 27.74 PLN with a low forecast of 15.66 PLN and a high forecast of 40.95 PLN.

What is Celon Pharma SA's Revenue forecast?
Projected CAGR
17%

For the last 8 years the compound annual growth rate for Celon Pharma SA's revenue is 6%. The projected CAGR for the next 3 years is 17%.

Back to Top